---
document_datetime: 2025-04-07 15:46:52
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/mvabea-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: mvabea-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.6160725
conversion_datetime: 2025-12-25 05:29:00.34902
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## MVABEA

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                              |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0023               | Renewal of the marketing authorisation. | 30/01/2025                          | 28/03/2025                                  | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Mvabea in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| II/0021   | Update of sections 4.6 and 5.1 of the SmPC in order                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 27/02/2025   | SmPC, Annex   | SmPC new text                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|           | to update information on pregnancy based on final results from study VAC52150EBL3010 listed as a category 3 study in the RMP as well as study VAC52150EBL3008 and two post-authorisation vaccination campaigns. Study VAC52150EBL3010 is a phase 3 open-label randomized clinical trial to evaluate the safety, reactogenicity and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy pregnant women. The Package Leaflet is updated accordingly. The RMP version 4.1 has also been submitted. In addition, the MAH took the opportunity to introduce minor changes to the Product Information and to update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data |              | II and PL     | Section 4.6 Pregnancy In Study EBL3010, a Phase III open label, randomised, controlled study in healthy pregnant women, the percentage of women with any adverse maternal/foetal or neonatal/infant outcome was similar in 977 (51 in the first trimester) vaccinated pregnant women versus 1 000 (51 in the first trimester) unvaccinated pregnant women (0.4% versus 0.5% for miscarriage, 0.9% versus 1.1% for congenital anomalies, 2.7% versus 3.1% for preterm birth, and 4.7% versus 5.0% for low birth weight). Twenty-two infant deaths were reported throughout the entire study: 12/964 (1.2%) infants born to vaccinated pregnant women versus 10/981 (1.0%) born to unvaccinated pregnant women. Amongst these, there was a numerical imbalance in cases of neonatal death (1.1% versus 0.5%), including neonatal deaths related to hypoxic ischaemic encephalopathy. These rates are below the background neonatal death rate of 20 per 1000 live births. Immunogenicity data was also obtained in this study. Data from 492 additional pregnancy outcomes (134 in the first trimester) from an open label Phase III study (EBL3008) and vaccination campaigns (EBL4002) and (EBL4004) revealed no vaccine associated congenital anomalies or foetal/neonatal toxicity. [â€¦] It is preferred to only use Mvabea during pregnancy if the benefits of immediate vaccination outweigh the potential risks. Section 5.1 Immunogenicity data in pregnant and postpartum women |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                       |            |            |             | and infants The immune response to the 2 dose primary vaccination regimen given in an 8 week interval was assessed in pregnant women and a subset of their infants in study EBL3010. The control group received the vaccine 6 10 weeks postpartum in the same study. In this study, 99.4% of study participants mounted a binding antibody response to EBOV GP, 21 days post dose 2. At 21 days post dose 2, the GMC was numerically lower in pregnant women than in the control group. At 365 days post dose 1 (i.e. 1 year post dose 1), the difference between pregnant women and postpartum women was no longer present. For pregnant women, 99.3% (145/146) of women had a positive sample with a GMC of 2186 EU/mL at postpartum Day 1 (cord blood). In infants born to women vaccinated during pregnancy, 94.7% (71/75) had a positive sample with a GMC of 264 EU/mL at postpartum Day 99 (i.e. 14 weeks of age). For more information, please refer to the Summary of Product Characteristics.   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0022              | Annual re-assessment.                                                                                                 | 17/10/2024 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| PSUSA/10857 /202309 | Periodic Safety Update EU Single assessment - ebola vaccine (Ad26.ZEBOV-GP [recombinant], MVA-BN- Filo [recombinant]) | 25/04/2024 | 25/04/2024 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10857/202309.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| S/0019              | Third annual re-assessment.                                                                                           | 12/10/2023 | n/a        |             | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           |                                                    |            |            |             | medicinal product, concluded that marketing authorisation of MVABEA should be maintained.   |
|-----------|----------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------|
| II/0018/G | This was an application for a group of variations. | 20/07/2023 | 24/07/2024 | SmPC and PL | For more information, please refer to the Summary of Product Characteristics.               |

<div style=\"page-break-after: always\"></div>

|                     | the local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |     |                                                                                                                                                                                                                                                                 |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10857 /202209 | Periodic Safety Update EU Single assessment - ebola vaccine (Ad26.ZEBOV-GP [recombinant], MVA-BN- Filo [recombinant])                                                                                                                                                                                                                                                                                     | 14/04/2023 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                               |
| IB/0016             | B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product                                                                                                                                                                                                                                                                                  | 08/12/2022 | n/a |                                                                                                                                                                                                                                                                 |
| PSUSA/10857 /202203 | Periodic Safety Update EU Single assessment - ebola vaccine (Ad26.ZEBOV-GP [recombinant], MVA-BN- Filo [recombinant])                                                                                                                                                                                                                                                                                     | 27/10/2022 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                               |
| S/0015              | Second annual re-assessment                                                                                                                                                                                                                                                                                                                                                                               | 13/10/2022 | n/a | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of MVABEA should be maintained. |
| IB/0014             | B.I.b.2.a - Change in test procedure for AS or                                                                                                                                                                                                                                                                                                                                                            | 05/07/2022 | n/a |                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|                     | starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                         |            |            |                 |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| IB/0012             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                | 10/05/2022 | n/a        |                 |                                   |
| PSUSA/10857 /202109 | Periodic Safety Update EU Single assessment - ebola vaccine (Ad26.ZEBOV-GP [recombinant], MVA-BN- Filo [recombinant])                                                                                                                                                                                                                                                                        | 05/05/2022 | n/a        |                 | PRAC Recommendation - maintenance |
| IB/0011             | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                                                                  | 18/02/2022 | n/a        |                 |                                   |
| IB/0008             | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                          | 22/12/2021 | n/a        |                 |                                   |
| IAIN/0010/G         | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site | 21/12/2021 | 16/12/2022 | Annex II and PL |                                   |
| IB/0007             | B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a                                                                                                                                                                                                                                                                                    | 05/11/2021 | n/a        |                 |                                   |

<div style=\"page-break-after: always\"></div>

|                     | new specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                                         |            |            |                                                                                                                                                                                                                                                                 |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10857 /202103 | Periodic Safety Update EU Single assessment - ebola vaccine (Ad26.ZEBOV-GP [recombinant], MVA-BN- Filo [recombinant])                                                                                                                                                                                                                       | 28/10/2021 | n/a        | PRAC Recommendation - maintenance                                                                                                                                                                                                                               |
| S/0006              | First annual re-assessment.                                                                                                                                                                                                                                                                                                                 | 14/10/2021 | n/a        | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of MVABEA should be maintained. |
| N/0004              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                            | 21/07/2021 | 16/12/2022 |                                                                                                                                                                                                                                                                 |
| PSUSA/10857 /202009 | Periodic Safety Update EU Single assessment - ebola vaccine (Ad26.ZEBOV-GP [recombinant], MVA-BN- Filo [recombinant])                                                                                                                                                                                                                       | 06/05/2021 | n/a        | PRAC Recommendation - maintenance                                                                                                                                                                                                                               |
| IB/0003/G           | This was an application for a group of variations. B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product | 14/04/2021 | n/a        |                                                                                                                                                                                                                                                                 |
| IB/0001             | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                                                                     | 24/11/2020 | n/a        |                                                                                                                                                                                                                                                                 |